Controversies in immunotherapy for anti-NMDA receptor encephalitis: a scoping review with a proposal of operational definitions

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER-VERLAG ITALIA SRL
Autores
BANDEIRA, Geovanni Guimaraes
LIMA, Pedro Lucas Grangeiro de Sa Barreto
ARAUJO, David Augusto Batista Sa
PINHEIRO, Maria Suelly Nogueira
MOTA, Luciano de Albuquerque
SIMAO, Rafael Machado
CARVALHO, Francisco Matheus Oliveira de
VAZQUEZ, Fernando Degani
GAMA, Vitor Carneiro de Vasconcelos
QUEIROZ, Danton Campos de
Citação
NEUROLOGICAL SCIENCES, v.44, n.12, p.4307-4312, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Anti-NMDA receptor encephalitis (NMDARE), an autoimmune encephalitis associated with autoantibodies against the N-methyl-D-aspartate (NMDA) receptor, affects predominantly young women and is associated with psychiatric symptoms, seizures, movement disorders, and autonomic instability. Traditional treatments of anti-NMDA receptor encephalitis involve corticosteroids, intravenous immunoglobulin, plasmapheresis, cyclophosphamide, and rituximab. However, many controversies remain in the treatment for NMDA receptor encephalitis, such as optimal timing and combination of different immunotherapies, the role of newer strategies (e.g., bortezomib or tocilizumab) for severe and refractory patients, and the need or not for long-term immunosuppression. Our goal was to perform a scoping review to discuss the controversial topics of immunotherapy for NMDA receptor encephalitis and propose operational definitions to guide clinical practice and future research in the field.
Palavras-chave
Anti-NMDA encephalitis, Treatment, Glucocorticoids, Immunotherapy
URI
https://observatorio.fm.usp.br/handle/OPI/59179
Referências
  1. Abboud H, 2021, J NEUROL NEUROSUR PS, V92, P757, DOI 10.1136/jnnp-2020-325300
  2. Armangue T, 2015, NEUROLOGY, V84, P1379, DOI 10.1212/WNL.0000000000001425
  3. Armangue T, 2014, CURR OPIN NEUROL, V27, P361, DOI 10.1097/WCO.0000000000000087
  4. Barry H, 2015, BJPSYCH BULL, V39, P19, DOI 10.1192/pb.bp.113.045518
  5. Dalmau J, 2007, ANN NEUROL, V61, P25, DOI 10.1002/ana.21050
  6. Dalmau J, 2019, LANCET NEUROL, V18, P1045, DOI 10.1016/S1474-4422(19)30244-3
  7. Dalmau J, 2014, NEURO-ONCOLOGY, V16, P771, DOI 10.1093/neuonc/nou030
  8. Dalmau J, 2011, LANCET NEUROL, V10, P63, DOI 10.1016/S1474-4422(10)70253-2
  9. Dalmau J, 2008, LANCET NEUROL, V7, P1091, DOI 10.1016/S1474-4422(08)70224-2
  10. Deng B, 2019, J NEUROIMMUNOL, V330, P81, DOI 10.1016/j.jneuroim.2019.02.008
  11. Dinoto A, 2022, CNS DRUGS, V36, P919, DOI 10.1007/s40263-022-00943-z
  12. Dou XJ, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.606923
  13. Florance NR, 2009, ANN NEUROL, V66, P11, DOI 10.1002/ana.21756
  14. Gable MS, 2012, CLIN INFECT DIS, V54, P899, DOI 10.1093/cid/cir1038
  15. Gresa-Arribas N, 2014, LANCET NEUROL, V13, P167, DOI 10.1016/S1474-4422(13)70282-5
  16. Huang XQ, 2015, INT J CLIN EXP MED, V8, P18927
  17. Lee WJ, 2021, NEUROTHERAPEUTICS, V18, P474, DOI 10.1007/s13311-020-00921-7
  18. Nóbrega PR, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00176
  19. Nóbrega PR, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00472
  20. Nosadini M, 2019, DEV MED CHILD NEUROL, V61, P458, DOI 10.1111/dmcn.14020
  21. Nosadini M, 2019, DEV MED CHILD NEUROL, V61, P1101, DOI 10.1111/dmcn.14267
  22. Onugoren MD, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000207
  23. Rosch RE, 2018, P NATL ACAD SCI USA, V115, pE9916, DOI 10.1073/pnas.1804846115
  24. Sakpichaisakul K, 2018, J NEUROIMMUNOL, V324, P119, DOI 10.1016/j.jneuroim.2018.09.007
  25. Seki M, 2008, J NEUROL NEUROSUR PS, V79, P324, DOI 10.1136/jnnp.2007.136473
  26. Shin YW, 2018, ANN CLIN TRANSL NEUR, V5, P598, DOI 10.1002/acn3.557
  27. Titulaer MJ, 2013, LANCET NEUROL, V12, P157, DOI 10.1016/S1474-4422(12)70310-1
  28. Turnbull MT, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00188
  29. Vasconcelos GD, 2021, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.606350
  30. Wagner JN, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00434
  31. Yang RN, 2021, BRAIN BEHAV, V11, DOI 10.1002/brb3.2277
  32. Yang S, 2021, FRONT PEDIATR, V9, DOI 10.3389/fped.2021.605042
  33. Yang XZ, 2018, CHINESE MED J-PEKING, V131, P156, DOI 10.4103/0366-6999.222327
  34. Yang Y, 2021, J CLIN APHERESIS, V36, P886, DOI 10.1002/jca.21938
  35. Zhang BJ, 2021, J NEUROL SCI, V428, DOI 10.1016/j.jns.2021.117568
  36. Zhang Y, 2021, ANN CLIN TRANSL NEUR, V8, P763, DOI 10.1002/acn3.51313
  37. Zhang Y, 2019, NEUROTHERAPEUTICS, V16, P828, DOI 10.1007/s13311-019-00725-4

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC